Evidence map›Paper›PMID 39373858›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2024

Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway.

Wenhao Xiu, Yujia Zhang, Dongfang Tang, Sau Har Lee, Rui Zeng, Tingjie Ye, Hua Li, Yanlin Lu, Changtai Qin, Yuxi Yang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wenhao Xiu *School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yujia Zhang *School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Dongfang Tang *Department of Thoracic Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Sau Har LeeSchool of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Selangor, Malaysia.
Rui ZengSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Tingjie YeSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Hua LiSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yanlin LuDepartment of Oncology and Institute of Traditional Chinese Medicine in Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Changtai QinSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yuxi YangSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Xiaofeng YanSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Xiaoling WangSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Xudong HuSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Maoquan ChuSchool of Life Science and Technology, Tongji University, Shanghai, China.
Zhumei SunSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. sunzhumei2000@126.com.
Wei XuSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. wei-xu11@tsinghua.org.cn.

Funding

NSFC grant No.82204673the budget research project of Shanghai University of Traditional Chinese Medicine No.2021LK018
6 · The paper itself

Abstract

purposeTaxol is the first-line chemo-drug for advanced non-small cell lung cancer (NSCLC), but it frequently causes acquired resistance, which leads to the failure of treatment. Therefore, it is critical to screen and characterize the mechanism of the taxol-resistance reversal agent that could re-sensitize the resistant cancer cells to chemo-drug.

methodThe cell viability, sphere-forming and xenografts assay were used to evaluate the ability of ASIV to reverse taxol-resistance. Immunohistochemistry, cytokine application, small-interfering RNA, small molecule inhibitors, and RNA-seq approaches were applied to characterize the molecular mechanism of inhibition of epiregulin (EREG) and downstream signaling by ASIV to reverse taxol-resistance.

resultsASIV reversed taxol resistance through suppression of the stemness-associated genes of spheres in NSCLC. The mechanism exploration revealed that ASIV promoted the K48-linked polyubiquitination of EREG along with degradation. Moreover, EREG could be triggered by chemo-drug treatment. Consequently, EREG bound to the ErbB receptor and activated the ERK signal to regulate the expression of the stemness-associated genes. Inhibition of EREG/ErbB/ERK could reverse the taxol-resistance by inhibiting the stemness-associated genes. Finally, it was observed that TGFβ and Hedgehog signaling were downstream of EREG/ErbB/ERK, which could be targeted using inhibitors to reverse the taxol resistance of NSCLC.

conclusionsThese findings revealed that inhibition of EREG by ASIV reversed taxol-resistance through suppression of the stemness of NSCLC via EREG/ErbB/ERK-TGFβ, Hedgehog axis.

Indexed as

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmEpiregulinErbB ReceptorsHedgehog ProteinsLung NeoplasmsMice, NudePaclitaxelSignal TransductionTransforming Growth Factor betaTriterpenesAnimalsCell Line, TumorHumansMAP Kinase Signaling SystemMiceEpiregulinErbB ReceptorsEREG protein, humanHedgehog ProteinsPaclitaxelSaponinsTransforming Growth Factor betaTriterpenesASIVEREGNon-small cell lung cancerStemnessTaxol-resistance

Identifiers

PMID39373858
PMCPMC12974003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.